Genentech, a member of the Roche Group, recently announced its Phase II IMmotion150 study delivered promising results.
The study compared Tecentriq plus Avastin and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (RCC). Results showed a 36 percent reduction in the risk of disease worsening or death for people whose disease expressed PD-L1 (programmed death-ligand 1) and were treated with TECENTRIQ plus Avastin as opposed to people treated with sunitinib alone.
“These Phase II results support the scientific rationale for potentially combining TECENTRIQ and Avastin in people with this type of kidney cancer,” Dr. Sandra Horning, chief medical officer and head of Global Product Development, said in a statement. “There is a significant need for new treatment options for people living with advanced RCC, a disease where currently only about one in 10 people are alive beyond five years following diagnosis.”
Genentech is evaluating the drug combination in a Phase III study for people with previously untreated, locally advanced or metastatic RCC.
Alerts Sign-up